Reconstituting retroviral (ReCon) vectors facilitating delivery of cytotoxic genes in cancer gene therapy approaches

Journal of Gene Medicine

Volumn 10, Issue 2, 2008, Pages 113-122

  Brandtner, Eva Maria ^a   Kodajova, Petra ^b   Hlavaty, Juraj ^b   Jandl, Gerrit ^b   Tabotta, Walter ^a   Salmons, Brian ^a   Günzburg, Walter H ^b   Hohenadl, Christine ^a,b,c  

^a Austrianova Biomanufacturing Company   (Austria)

^b UNIVERSITY OF VETERINARY MEDICINE   (Austria)

^c PAUL EHRLICH INSTITUT   (Germany)

Author keywords

Cancer gene therapy; Cytotoxic gene; Expression targeting; Retroviral vector; Vector optimization

Indexed keywords

ACID PROTEIN; ANTINEOPLASTIC AGENT; CYTOTOXIC AGENT; LAMBDA HOLIN; RETROVIRUS VECTOR; UNCLASSIFIED DRUG; VIRUS PROTEIN;

3' UNTRANSLATED REGION; 5' UNTRANSLATED REGION; ANIMAL CELL; ARTICLE; CANCER GENE THERAPY; CELL KILLING; CELL SPECIFICITY; CONTROLLED STUDY; CYTOMEGALOVIRUS; CYTOTOXICITY; ENHANCER REGION; GENE DELETION; GENE INSERTION; GENE REPLICATION; GENETIC TRANSDUCTION; HEPATITIS VIRUS; HUMAN; HUMAN CELL; LONG TERMINAL REPEAT; MOUSE MAMMARY TUMOR ONCOVIRUS; MUTATIONAL ANALYSIS; NONHUMAN; POLYADENYLATION; PRIORITY JOURNAL; PROMOTER REGION; RETROVIRUS INFECTION; SIGNAL TRANSDUCTION; TARGET CELL; TISSUE SPECIFICITY; TRANSCRIPTION REGULATION; VIRAL GENE DELIVERY SYSTEM; VIRUS INFECTIVITY; VIRUS TITRATION; WHEY;

ANIMALS; BASE SEQUENCE; CELL DEATH; CYTOTOXINS; GENE THERAPY; GENETIC ENGINEERING; GENETIC VECTORS; HELA CELLS; HUMANS; MICE; MOLECULAR SEQUENCE DATA; NEOPLASMS; NIH 3T3 CELLS; ORGAN SPECIFICITY; POLYADENYLATION; PROMOTER REGIONS (GENETICS); RETROVIRIDAE; SEQUENCE DELETION; TRANSDUCTION, GENETIC;

BACTERIA (MICROORGANISMS); CYTOMEGALOVIRUS; WOODCHUCK HEPATITIS VIRUS;

EID: 39449107788     PISSN: 1099498X     EISSN: 15212254     Source Type: Journal    
DOI: 10.1002/jgm.1143     Document Type: Article

References (45)

1. Denny WA. Tumor-activated prodrugs - a new approach to cancer therapy. Cancer Invest 2004; 22: 604-619.
2. McKeown SR, Ward C, Robson T. Gene-directed enzyme prodrug therapy: a current assessment. Curr Opin Mol Ther 2004; 6: 421-435.
3. Russell PJ, Khatri A. Novel gene-directed enzyme prodrug therapies against prostate cancer. Exp Opin Invest Drugs 2006; 15: 947-61.
4. Tabotta W, Klein D, Hohenadl C, et al. Genetic reshuffling reconstitutes functional expression cassettes in retroviral vectors. J Gene Med 2001; 3: 418-426.
5. Hlavaty J, Schittmayer M, Stracke A, et al. Effect of posttranscriptional regulatory elements on transgene expression and virus production in the context of retrovirus vectors. Virology 2005; 341: 1-11.
6. Hlavaty J, Portsmouth D, Stracke A, et al. Effects of sequences of prokaryotic origin on titer and transgene expression in retroviral vectors. Virology 2004; 330: 351-360.
7. Hlavaty J, Stracke A, Klein D, et al. Multiple modifications allow high-titer production of retroviral vectors carrying heterologous regulatory elements. J Virol 2004; 78: 1384-1392.
8. Günzburg WH, Hlavaty J, Indik S, et al. New generations of retroviraI vector for safe, efficient and targeted gene therapy. Gene Ther Mol Biol 2006; 10: 185-192.
9. Lipnik K, Petznek H, Renner-Muller I, et al. A 470 bp WAP-promoter fragment confers lactation independent, progesterone regulated mammary-specific gene expression in transgenic mice. Transgenic Res 2005; 14: 145-158.
10. Lipnik K, Greco O, Scott S, et al. Hypoxia- and radiation-inducible, breast cell-specific targeting of retroviral vectors. Virology 2006; 349: 121-133.
11. Özturk-Winder F, Renner M, Klein D, et al. The murine whey acidic protein promoter directs expression to human mammary tumors after retroviral transduction. Cancer Gene Ther 2002; 9: 421-431.
12. Saller RM, Özturk F, Salmons B, et al. Construction and characterization of a hybrid mouse mammary tumor virus/murine leukemia virus-based retroviral vector. J Virol 1998; 72: 1699-1703.
13. Agu CA, Klein I, Schwab S, et al. The cytotoxic activity of the bacteriophage lambda-holin protein reduces tumour growth rates in mammary cancer cell xenograft models. J Gene Med 2006; 8: 229-241.
14. Pambalk K, Hohenadl C, Salmons B, et al. Specific packaging of spliced retroviral vector transcripts lacking the Psi-region. Biochem Biophys Res Commun 2002; 293: 239-246.
15. Ho SN, Hunt HD, Horton RM, et al. Site-directed mutagenesis by overlap extension using the polymerase chain reaction. Gene 1989; 77: 51-59.
16. Salmons B, Groner B, Calberg-Bacq CM, et al. Production of mouse mammary tumor virus upon transfection of a recombinant proviral DNA into cultured cells. Virology 1985; 144: 101-114.
17. Capaldo-Kimball F, Barbour SD. Involvement of recombination genes in growth and viability ofEscherichia coli K-12. J Bacteriol 1971; 106: 204-212.
18. Takahashi N, Yoshikura H, Kobayashi I. An Escherichia coli strain, BJ5183, that shows highly efficient conservative (two-progeny) DNA double-strand break repair of restriction breaks. Gene 2003; 303: 89-97.
19. Bubeck P, Winkler M, Bautsch W. Rapid cloning by homologous recombination in vivo. Nucleic Acids Res 1993; 21: 3601-3602.
20. Chartier C, Degryse E, Gantzer M, et al. Efficient generation of recombinant adenovirus vectors by homologous recombination in Escherichia coli. J Virol 1996; 70: 4805-4810.
21. Mosmann T. Rapid colorimetric assay for cellular growth and survival: application to proliferation and cytotoxicity assays. J Immunol Methods 1983; 65: 55-63.
22. Lusky M, Botchan M. Inhibition of SV40 replication in simian cells by specific pBR322 DNA sequences. Nature 1981; 293: 79-81.
23. Donello JE, Loeb JE, Hope TJ. Woodchuck hepatitis virus contains a tripartite posttranscriptional regulatory element. J Virol 1998; 72: 5085-5092.
24. Bacharach E, Gonsky J, Lim D, et al. Deletion of a short, untranslated region adjacent to the polypurine tract in Moloney murine leukemia virus leads to formation of aberrant 5′ plusstrand DNA ends in vivo. J Virol 2000; 74: 4755-4764.
25. Kulpa D, Topping R, Telesnitsky A. Determination of the site of first strand transfer during Moloney murine leukemia virus reverse transcription and identification of strand transfer-associated reverse transcriptase errors. EMBO J 1997; 16: 856-865.
26. Robson ND, Telesnitsky A. Selection of optimal polypurine tract region sequences during Moloney murine leukemia virus replication. J Virol 2000; 74: 10293-10303.
27. Yu SS, Kim JM, Kim S. The 17 nucleotides downstream from the env gene stop codon are important for murine leukemia virus packaging. J Virol 2000; 74: 8775-8780.
28. Rungaldier S, Nejad Asl SB, Günzburg WH, et al. Abundant authentic MMTV-Env production from a recombinant provirus lacking the major LTR promoter. Virology 2005; 342: 201-214.
29. Lin CQ, Dempsey PJ, Coffey RJ, et al. Extracellular matrix regulates whey acidic protein gene expression by suppression of TGF-alpha in mouse mammary epithelial cells: studies in culture and in transgenic mice. J Cell Biol 1995; 129: 1115-1126.
30. Schoenenberger CA, Zuk A, Groner B, et al. Induction of the endogenous whey acidic protein (Wap) gene and a Wap-myc hybrid gene in primary murine mammary organoids. Dev Biol 1990; 139: 327-337.
31. Schambach A, Wodrich H, Hildinger M. et al. Context dependence of different modules for posttranscriptional enhancement of gene expression from retroviral vectors. Mol Ther 2000; 2: 435-445.
32. Schambach A, Bohne J. Baum C, et al. Woodchuck hepatitis virus post-transcriptional regulatory element deleted from X protein and promoter sequences enhances retroviral vector titer and expression. Gene Ther 2006; 13: 641-645.
33. Zufferey R. Donello JE, Trono D, et al. Woodchuck hepatitis virus posttranscriptional regulatory element enhances expression of transgenes delivered by retroviral vectors. J Virol 1999; 73: 2886-2892.
34. Klein R, Ruttkowski B, Knapp E, et al. WPRE-mediated enhancement of gene expression is promoter and cell line specific. Gene 2006; 372: 153-161.
35. Popa I, Harris ME, Donello JE, et al. CRM1-dependent function of a cis-acting RNA export element. Mol Cell Biol 2002; 22: 2057-2067.
36. Cobrinik D, Aiyar A, Ge Z, et al. Overlapping retrovirus US sequence elements are required for efficient integration and initiation of reverse transcription. J Virol 1991; 65: 3864-3872.
37. Murphy JE, Goff SP. Construction and analysis of deletion mutations in the US region of Moloney murine leukemia virus: effects on RNA packaging and reverse transcription. J Virol 1989; 63:319-327.
38. Brandtner E-M, Kodajova P, Knapp E, et al. Quantification and characterization of autotransduction in retrovirus producer cells. Hum Gene Ther 19; 2008: DOI:10.1089/hum.2007.071.
39. Ui M, Takada M. Arai T, et al. Retrovirus vectors designed for efficient transduction of cytotoxic or cytostatic genes. Gene Ther 1999; 6: 1670-1678.
40. Diaz RM, Bateman A, Emiliusen L, et al. A lentiviral vector expressing a fusogenic glycoprotein for cancer gene therapy. Gene Ther 2000; 7: 1656-1663.
41. Qiao J, Caruso M. PG13 packaging cells produce recombinant retroviruses carrying a diphtheria toxin mutant which kills cancer cells. J Virol 2002; 76: 7343-7348.
42. Peng H, Usas A, Gearhart B, et al. Development of a self-inactivating tet-on retroviral vector expressing bone morphogenetic protein 4 to achieve regulated bone formation. Mol Ther 2004; 9: 885-894.
43. Pluta K, Luce MJ, Bao L, et al. Tight control of transgene expression by lentivirus vectors containing second-generation tetracycline-responsive promoters. J Gene Med 2005; 7: 803-817.
44. Hauser O, Prieschl-Grassauer E, Salmons B. Encapsulated, genetically modified cells producing in vivo therapeutics. Curr Opin Mol Ther 2004; 6: 412-420.
45. Saller RM, Indraccolo S, Coppola V, et al. Encapsulated cells producing retroviral vectors for in vivo gene transfer. J Gene Med 2002; 4: 150-160.